Back to News
Market Impact: 0.2
Polyrizon Reports Enrollment Of First Patient In Trial For Allergy Nasal Spray NASARIX
Source: Nasdaq
Healthcare & Biotech
Polyrizon enrolled the first patient in its clinical study of NASARIX for seasonal allergic rhinitis. The milestone advances the clinical-stage biotech program, but the article provides no efficacy, safety, timeline, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
PLRZ0.55
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Jefferies raises Inovio stock price target on regulatory win
- Humana lifts annual profit forecast as medical costs ease
- Truist raises Vericel stock price target on MACI growth momentum